Multiple myeloma patients who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated progression on/within 60 days of completion of the last therapy may benefit from pomalidomide plus dexamethasone.
In the phase 2, single-arm MM-014 trial of DPd (pomalidomide + dexamethasone + daratumumab), patients with RRMM who received 1 or 2 prior treatment lines demonstrated an ORR of nearly 78.6% in the ITT population. The complete response (CR) was 26.8%; very-good partial response (VGPR), 25.9%; PR, 25.9%.
In other results, patients who relapsed after taking lenalidomide or who were refractory to lenalidomide had an ORR of 81.5% and 77.6%, respectively. As for secondary outcomes, median PFS was 23.7 months in the ITT population and median OS was 56.7 months. Overall, 8.9% of patients discontinued secondary to adverse events.
What is your treatment threshold to proceed to 2L therapy? How do you determine whether to dose adjust medications or change therapy altogether?
-
Venu Madhav Konala, GCS/Northside2yrDPD with the above data is an option, and DKD - the carfilzomib-based regimen is also an option. It all depends on the patient's situation, what prior regimes the patient Show More
-
NIHAL ABDULLA2yrSo with patients on maintenance once levels start going up just by adjusting dose usually buys 6 months on an average. Hence during that time need to start preparing and Show More
